BAM
ONCE

Belpointe Asset Management’s Spark Therapeutics, Inc. Common Stock ONCE Stock Holding History

Belpointe Asset Management’s Portfolio ONCE Stock Details ONCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-4,520
Closed -$403K – 504
2017
Q3 		$403K Buy
+4,520
New +$343K 0.09% 248

Other funds holding ONCE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Belpointe Asset Management's ONCE Position: Q4 2017 in Review

Belpointe Asset Management sold out of Spark Therapeutics, Inc. Common Stock (ONCE) in Q4 2017, closing a stake of 4,520 shares — an estimated $403K sold.

Belpointe Asset Management first reported a position in ONCE in Q3 2017 and held it in 1 quarter. The position peaked at $403K in Q3 2017. 160 funds tracked by Wall St. Rank hold ONCE as of Q4 2017.

  • Belpointe Asset Management reported no remaining Spark Therapeutics, Inc. Common Stock position as of Q4 2017 after selling out during the quarter.
  • Belpointe Asset Management sold 4,520 Spark Therapeutics, Inc. Common Stock shares in Q4 2017, an estimated $403K.
  • Belpointe Asset Management first reported a position in Spark Therapeutics, Inc. Common Stock in Q3 2017 and held it in 1 quarter.
  • Belpointe Asset Management's Spark Therapeutics, Inc. Common Stock position peaked at $403K in Q3 2017.
  • 160 funds tracked by Wall St. Rank held Spark Therapeutics, Inc. Common Stock as of Q4 2017.

Based on Belpointe Asset Management's 13F filing for Q4 2017, filed 15 Feb 2018.